Literature DB >> 16543775

Adjuvant treatment of pancreatic carcinoma in a clinically adapted mouse resection model.

Juergen Tepel1, Marie-Luise Kruse, Matthias Kapischke, Sieglinde Haye, Bence Sipos, Bernd Kremer, Holger Kalthoff.   

Abstract

BACKGROUND: The high rate of local recurrence after radical resection of pancreatic adenocarcinoma fosters intensive efforts to develop new approaches for adjuvant treatment. The established animal models show significant limitations in simulating an adjuvant therapeutic setting. For optimal approximation to the clinical situation we therefore improved a murine orthotopic human xenotransplantation model.
METHODS: Subtotal pancreatectomy in mice was performed after orthotopic inoculation of human pancreatic cancer cells and manifestation of solid tumours. The natural course of disease, tumour growth and metastases were analysed. Gemcitabine as a cytotoxic drug was tested in vitro on the cell line used in this model and the effect of adjuvant treatment with gemcitabine in vivo was investigated.
RESULTS: All tumour-resected animals showed local recurrence. Organ metastases occurred in 67% in resected compared to 25% of non-resected animals. Gemcitabine in vitro was ineffective, but as adjuvant monotherapy resulted in a highly significant reduction of tumour weight and metastatic events.
CONCLUSION: Subtotal pancreatectomy for xenotransplanted pancreatic cancer in SCID beige mice is feasible. Due to high rates of local recurrence and increased organ metastases, this model offers a relevant option for preclinical adjuvant testing, especially as in vitro and in vivo effects of cytotoxic drugs differ enormously.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16543775     DOI: 10.1159/000092027

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  4 in total

1.  Assessment of anti-inflammatory tumor treatment efficacy by longitudinal monitoring employing sonographic micro morphology in a preclinical mouse model.

Authors:  Sanjay Tiwari; Jan H Egberts; Olena Korniienko; Linda Köhler; Anna Trauzold; Claus C Glüer; Holger Kalthoff
Journal:  BMC Med Imaging       Date:  2011-06-23       Impact factor: 1.930

2.  The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.

Authors:  Karen Legler; Charlotte Hauser; Jan-Hendrik Egberts; Anna Willms; Carola Heneweer; Susann Boretius; Christoph Röcken; Claus-Christian Glüer; Thomas Becker; Michael Kluge; Oliver Hill; Christian Gieffers; Harald Fricke; Holger Kalthoff; Johannes Lemke; Anna Trauzold
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

3.  Drug Repositioning Inferred from E2F1-Coregulator Interactions Studies for the Prevention and Treatment of Metastatic Cancers.

Authors:  Deborah Goody; Shailendra K Gupta; David Engelmann; Alf Spitschak; Stephan Marquardt; Stefan Mikkat; Claudia Meier; Charlotte Hauser; Jan-Paul Gundlach; Jan-Hendrik Egberts; Hubert Martin; Toni Schumacher; Anna Trauzold; Olaf Wolkenhauer; Stella Logotheti; Brigitte M Pützer
Journal:  Theranostics       Date:  2019-02-20       Impact factor: 11.556

4.  Tumor necrosis factor induces tumor promoting and anti-tumoral effects on pancreatic cancer via TNFR1.

Authors:  Martin Chopra; Isabell Lang; Steffen Salzmann; Christina Pachel; Sabrina Kraus; Carina A Bäuerlein; Christian Brede; Ana-Laura Jordán Garrote; Katharina Mattenheimer; Miriam Ritz; Stefanie Schwinn; Carolin Graf; Viktoria Schäfer; Stefan Frantz; Hermann Einsele; Harald Wajant; Andreas Beilhack
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.